847361-67-5

Basic information

• Product Name: Cyclopropanecarboxamide, 1-(4-bromophenyl)-
• CAS NO: 847361-67-5
• Molecular Formula: C10H10BrNO
• Molecular Weight: 240.099
• Mol File: 847361-67-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxamide, 1-(4-bromophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxamide, 1-(4-bromophenyl)-(847361-67-5)
• EPA Substance Registry System: Cyclopropanecarboxamide, 1-(4-bromophenyl)-(847361-67-5)

Safety Data

• Hazardous Substances Data: 847361-67-5(Hazardous Substances Data)

Usage

Description

Cyclopropanecarboxamide, 1-(4-bromophenyl)-, also known as 1-(4-bromophenyl)cyclopropanecarboxamide, is a chemical compound with the molecular formula C10H10BrNO. It is an amide derivative that features a cyclopropane ring and a bromophenyl group. This unique structure and reactivity make it a valuable intermediate in the synthesis of complex organic molecules, particularly in the fields of pharmaceuticals and agrochemicals.

Uses

Used in Organic Chemistry:
Cyclopropanecarboxamide, 1-(4-bromophenyl)is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable intermediate in the production of complex organic molecules.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Cyclopropanecarboxamide, 1-(4-bromophenyl)is utilized for the development of new drugs. Its specific structural features contribute to the design and synthesis of potential therapeutic agents.
Used in Materials Science:
Although not explicitly mentioned in the provided materials, Cyclopropanecarboxamide, 1-(4-bromophenyl)may have potential applications in materials science due to its unique structural properties.
Used in Catalysis:
Similarly, the compound may also find use in catalysis, another field where its structural and reactivity features could be advantageous, although this application is not detailed in the provided materials.

Upstream product

• 345965-52-8 1-(4-bromophenyl)cyclopropanecarboxylic acid 
• 16532-79-9 4-Bromophenylacetonitrile 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 543-27-1 isobutyl chloroformate 

Downstream Products

• 854267-93-9 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide 
• 1316736-14-7 1-(4-bromophenyl)cyclopropanecarbothioamide 
• 1316736-08-9 2-(1-(4-azidophenyl)cyclopropyl)-4-(pyridin-4-yl)thiazole 
• 1259967-32-2 4'-(1-carbamoylcyclopropyl)biphenyl-4-carboxylic acid 

Relevant articles and documents

Examining the mechanism of action of a kinesin inhibitor using Stable Isotope Labeled Inhibitors for Cross-Linking (SILIC)

It is difficult to determine a chemical inhibitor's binding site in multiprotein mixtures, particularly when high-resolution structural studies are not straightforward. Building upon previous research involving photo-cross-linking and the use of mixtures of stable isotopes, we report a method, Stable Isotope Labeled Inhibitors for Cross-linking (SILIC), for mapping a small molecule inhibitor's binding site in its target protein. In SILIC, structure-activity relationship data is used to design inhibitor analogues that incorporate a photo-cross-linking group along with either natural or 'heavy' stable isotopes. An equimolar mixture of these inhibitor analogues is cross-linked to the target protein to yield a robust signature for identifying inhibitor-modified peptide fragments in complex mass spectrometry data. As a proof of concept, we applied this approach to an ATP-competitive inhibitor of kinesin-5, a widely conserved motor protein required for cell division and an anticancer drug target. This analysis, along with mutagenesis studies, suggests that the inhibitor binds at an allosteric site in the motor protein.

REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B

The instant invention relates to compounds of formula I, diagrammed below, wherein R3, E, D and Y are defined in the application, which are useful as reversible inhibitors of monoamine oxidase-B and/or monoamine oxidase-A, and therefore useful to treat or prevent neurological diseases or conditions in mammals, preferably humans.

CATHEPSIN INHIBITORS

This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.